BOK Financial’s Summit Therapeutics SMMT Stock Holding History

BOK Financial’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$2.07K	–	1115
2025 Q3	$2.07K	Buy	+100	New	+$2.42K	﹤0.01%	1065

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

BOK Financial's SMMT Position: Q4 2025 in Review

BOK Financial sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 100 shares — an estimated $2.07K sold.

BOK Financial first reported a position in SMMT in Q3 2025 and held it in 1 quarter. The position peaked at $2.07K in Q3 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

BOK Financial reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
BOK Financial sold 100 Summit Therapeutics shares in Q4 2025, an estimated $2.07K.
BOK Financial first reported a position in Summit Therapeutics in Q3 2025 and held it in 1 quarter.
BOK Financial's Summit Therapeutics position peaked at $2.07K in Q3 2025.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on BOK Financial's 13F filing for Q4 2025, filed 3 Feb 2026.